Claims for Patent: 10,047,141

Summary for Patent: 10,047,141

Title:	Method of manufacturing a protein by perfusion in media with a low amino acid concentration
Abstract:	Perfusion media are disclosed providing excellent cell density, titer and product quality for production of a therapeutic protein in a perfusion process.
Inventor(s):	Puchacz; Ela (Pleasanton, CA), Grove; James Russell (Mountain View, CA)
Assignee:	Coherus Biosciences, Inc. (Redwood City, CA)
Application Number:	14/609,225
Patent Claims:	1. A method for manufacturing a protein comprising the step of producing the protein via perfusion in the presence of a feed medium comprising a total amino acid concentration of less than 70 mM, wherein a protein titer of at least 300 .mu.g/mL is achieved in the step of producing the protein, and wherein the protein is a TNFR (tumor necrosis factor receptor)-Fc fusion protein or an anti-TNF antibody. 2. The method of claim 1 wherein the feed medium comprises a total amino acid concentration in a range selected from the group consisting of: 15 to 20 mM; 20 to 25 mM; 25 to 30 mM; 30 to 35 mM; 35 to 40 mM; 40 to 45 mM; 45 to 50 mM; 50 to 55 mM; 55 to 60 mM; 60 to 65 mM; and between 65 and 70mM. 3. The method of claim 1 wherein the protein is selected from the group consisting of etanercept, adalimumab, infliximab, and a biosimilar thereof. 4. The method of claim 1 wherein the feed medium comprises one or more of the following: a base medium, cottonseed hydrolysate, dexamethasone, ManNAc (N-acetylmannosamine), and/or D-(+)-Galactose. 5. The method of claim 1 further comprising prior to the protein production step, preparing a mixture comprising cells capable of expressing a desired therapeutic protein, and a culture medium suitable for conducting such expression; and wherein the protein production step comprises (a) in a suitable vessel containing the mixture, causing the cells to produce the protein, and (b) periodically or continuously removing spent culture medium from, and adding fresh culture medium to, the vessel. 6. The method of claim 5 where the cells are CHO (Chinese hamster ovary) cells. 7. The method of claim 5 wherein, prior to the protein production step, the cells capable of expressing the protein are grown in a growth phase at a temperature selected from (i) 28.degree. to 37.degree. C.; and (ii) 35.degree. to 36.degree. C. 8. The method of claim 7 wherein the protein production step is carried out at a temperature selected from (i) greater than 32.degree. C.; (ii) greater than 34.degree. C.; (iii) greater than 35.degree. C.; (iv) the range of 33.degree. C. to 36.degree. C.; (v) the range of 35.degree. C. to 36.degree. C.; (vi) 32.5.degree. C.; (vii) 33.5.degree. C.; (viii) 34.5.degree. C.; and (ix) 35.5.degree. C. 9. The method of claim 8 wherein the protein being produced is selected from the group consisting of etanercept, adalimumab, infliximab, and a biosimilar thereof. 10. A perfusion method for producing a therapeutic protein comprising the steps of (a) preparing a mixture comprising CHO cells capable of expressing the protein, and a culture medium suitable for conducting such expression; (b) in a suitable vessel containing the mixture, causing the cells to produce the protein; and (c) periodically or continuously removing spent culture medium from, and adding fresh culture medium to, the vessel, wherein the culture medium comprises (i) a total amino acid concentration of 15 to 65 mM; and (ii) at least one selected from the group consisting of: a complex chemically-defined feed, dexamethasone, ManNAc (N-acetylmannosamine), cottonseed hydrolysate and D-(+)-galactose; wherein a protein titer of at least 300 .mu.mL is achieved in the step of producing the protein, and wherein the therapeutic protein is a TNFR (tumor necrosis factor receptor)-Fc fusion protein or an anti-TNF antibody. 11. The method of claim 10 wherein the therapeutic protein is selected from the group consisting of etanercept, adalimumab, infliximab, and a biosimilar thereof. 12. The method of claim 11 wherein the therapeutic protein is etanercept, or a biosimilar thereof. 13. The perfusion method of claim 12 wherein, prior to step (a), the cells capable of expressing etanercept or a biosimilar thereof are grown in a growth phase at a temperature selected from; (i) 28.degree. C. to 37.degree. C.; and (ii) 35.degree. to 36.degree. C. 14. The perfusion method of claim 13 wherein, during production of the etanercept or biosimilar thereof occurring in steps (b) and (c) the vessel is maintained at a temperature selected from (i) greater than 32.degree. C.; (ii) greater than 34.degree. C.; (iii) greater than 35.degree. C.; (iv) the range of 33.degree. C. to 36.degree. C.; (v) the range of 35.degree. C. to 36.degree. C.; (vi) 32.5.degree. C.; (vii) 33.5.degree. C.; (viii) 34.5.degree. C.; and (ix) 35.5.degree. C.

Details for Patent 10,047,141

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2039-02-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2039-02-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2039-02-26
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2039-02-26